PL362797A1 - Aerozolowe preparaty medyczne - Google Patents

Aerozolowe preparaty medyczne

Info

Publication number
PL362797A1
PL362797A1 PL02362797A PL36279702A PL362797A1 PL 362797 A1 PL362797 A1 PL 362797A1 PL 02362797 A PL02362797 A PL 02362797A PL 36279702 A PL36279702 A PL 36279702A PL 362797 A1 PL362797 A1 PL 362797A1
Authority
PL
Poland
Prior art keywords
aerosol formulations
salts
medical aerosol
medical
dosing
Prior art date
Application number
PL02362797A
Other languages
English (en)
Other versions
PL207377B1 (pl
Inventor
Rudi Müller-Walz
Carsten Niederländer
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec Ag filed Critical Jagotec Ag
Publication of PL362797A1 publication Critical patent/PL362797A1/pl
Publication of PL207377B1 publication Critical patent/PL207377B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PL362797A 2001-03-30 2002-03-11 Medyczny preparat aerozolowy, sposób wytwarzania medycznego preparatu aerozolowego oraz zastosowanie soli kwasów karboksylowych jako środków pomocniczych w tym preparacie PL207377B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH6012001 2001-03-30
CH15272001 2001-08-20
PCT/CH2002/000145 WO2002078671A1 (de) 2001-03-30 2002-03-11 Medizinische aerosolformulierungen

Publications (2)

Publication Number Publication Date
PL362797A1 true PL362797A1 (pl) 2004-11-02
PL207377B1 PL207377B1 (pl) 2010-12-31

Family

ID=25737693

Family Applications (1)

Application Number Title Priority Date Filing Date
PL362797A PL207377B1 (pl) 2001-03-30 2002-03-11 Medyczny preparat aerozolowy, sposób wytwarzania medycznego preparatu aerozolowego oraz zastosowanie soli kwasów karboksylowych jako środków pomocniczych w tym preparacie

Country Status (23)

Country Link
US (1) US20040101483A1 (pl)
EP (1) EP1372608B1 (pl)
JP (1) JP4824267B2 (pl)
CN (1) CN100496608C (pl)
AT (1) ATE375142T1 (pl)
AU (1) AU2002234476B2 (pl)
CA (1) CA2442415C (pl)
CY (1) CY1107128T1 (pl)
CZ (1) CZ301676B6 (pl)
DE (1) DE50211045D1 (pl)
DK (1) DK1372608T3 (pl)
ES (1) ES2292713T3 (pl)
HK (1) HK1064295A1 (pl)
HU (1) HU229798B1 (pl)
NO (1) NO332848B1 (pl)
NZ (1) NZ528640A (pl)
PL (1) PL207377B1 (pl)
PT (1) PT1372608E (pl)
RO (1) RO121172B1 (pl)
RU (1) RU2294737C2 (pl)
SK (1) SK286394B6 (pl)
WO (1) WO2002078671A1 (pl)
ZA (1) ZA200307161B (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
JP2005507881A (ja) 2001-09-17 2005-03-24 グラクソ　グループ　リミテッド 乾燥粉末医薬製剤
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
DE60304900T2 (de) * 2002-12-10 2006-10-19 Sepracor Inc., Marlborough Verwendung vom L-Tartrat Levalbuterolsalz in der Herstellung eines Dosierinhalators
GB0316335D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
EP1646370A1 (en) * 2003-07-11 2006-04-19 Glaxo Group Limited Pharmaceutical formulations
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0324918D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
DE602005007708D1 (de) * 2004-02-06 2008-08-07 Meda Pharma Gmbh & Co Kg Neue kombination von anticholinergen und beta mimetika zur behanldung von atemwegserkrankungen
ATE541570T1 (de) 2004-02-06 2012-02-15 Meda Pharma Gmbh & Co Kg Kombination von anticholinergika und hemmern von phosphodiesterase typ 4 zur behandlung von atemwegserkrankungen
CA2551780C (en) 2004-02-06 2013-02-26 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
HUE027076T2 (en) 2005-03-16 2016-08-29 Meda Pharma Gmbh & Co Kg Combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
EP1948596B1 (en) 2005-11-10 2011-10-19 Nicholas S. Bodor Soft anticholinergic esters
AU2012200449B2 (en) * 2005-12-21 2013-07-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE4 inhibitor and antileukotriene for the treatment of inflammatory diseases
CA2824075C (en) 2005-12-21 2015-04-28 Joachim Maus Combination of r, r-glycopyrrolate, formoterol, and a glucocorticoid for the treatment of inflammatory diseases
GB0602897D0 (en) * 2006-02-13 2006-03-22 Jagotec Ag Improvements In Or Relating To Dry Powder Inhaler Devices
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
GB0625303D0 (en) * 2006-12-19 2007-01-24 Jagotec Ag Improvements in and relating to metered dose inhalers
PT3111926T (pt) * 2009-05-29 2020-02-28 Pearl Therapeutics Inc Composições, métodos e sistemas para entrega respiratória de dois ou mais agentes ativos
AU2015201037C1 (en) * 2009-05-29 2017-07-27 Pearl Therapeutics, Inc. Respiratory delivery of active agents
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
AU2015201864A1 (en) * 2009-05-29 2015-04-30 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting B2 adrenergic receptor agonists and associated methods and systems
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
BR112012015335B1 (pt) * 2009-12-23 2021-05-18 Chiesi Farmaceutici S.P.A. formulação de aerossol para doença pulmonar obstrutiva crõnica
EA021604B1 (ru) 2009-12-23 2015-07-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Аэрозольная композиция для лечения астмы и copd
WO2011076843A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Combination therapy for copd
JP5513177B2 (ja) * 2010-03-08 2014-06-04 共同印刷株式会社 湿度インジケータとその製造方法、該製造方法に用いる湿度インジケータ用塗料
CN102416179B (zh) 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
BR112014008114B1 (pt) * 2011-10-11 2022-07-26 Chiesi Farmaceutici S.P.A. Micropartículas cristalinas, formulação farmacêutica, inalador dosimetrado pressurizado, formulação farmacêutica, processo para preparar microparticulas cristalinas e uso de micropartículas cristalinas
CN102362860A (zh) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
MX361286B (es) 2013-03-15 2018-12-03 Pearl Therapeutics Inc Métodos y sistemas para el acondicionamiento de materiales cristalinos de partículas.
US20190099344A1 (en) * 2016-04-11 2019-04-04 Suven Life Sciences Limited Topical spray formulation of glycopyrrolate

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55361B1 (pl) * 1970-09-17 1980-01-08
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
EP0561166A1 (de) * 1992-03-17 1993-09-22 ASTA Medica Aktiengesellschaft Dosieraerosole enthaltend den Wirkstoff D-18024 und verwandte Strukturen
MX9304585A (es) * 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
JPH06135815A (ja) * 1992-10-30 1994-05-17 Shiseido Co Ltd 経皮吸収抑制組成物
ZA939195B (en) * 1992-12-09 1995-06-08 Boehringer Ingelheim Pharma Stabilized medicinal aerosol solution formulations
DE4321288A1 (de) * 1993-06-26 1995-01-05 Solvay Fluor & Derivate Zusammensetzungen mit chlorfreien, gegebenenfalls wasserstoffhaltigen Fluorkohlenwasserstoffen
ATE233544T1 (de) * 1993-12-02 2003-03-15 Abbott Lab Aerosole als darreichungsform mit cfc-freiem treibmittel
US5589156A (en) * 1994-05-02 1996-12-31 Henry; Richard A. Prilocaine and hydrofluourocarbon aerosol preparations
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
ATE236617T1 (de) * 1994-12-22 2003-04-15 Astrazeneca Ab Aerosol-arzneiformulierungen
JP3707107B2 (ja) * 1995-09-18 2005-10-19 鈴木油脂工業株式会社 薬剤分散液及びその製造方法
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US6261472B1 (en) * 1996-11-04 2001-07-17 E. I. Du Pont De Nemours And Company Azeotrope-like compositions containing fluoroethane
US6361938B1 (en) * 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
CA2279648C (en) * 1997-01-30 2007-04-24 Alpenstock Holdings Limited Haemostatic aerosol composition
PT1014943E (pt) * 1997-02-05 2002-11-29 Jago Res Ag Formulacoes medicinais de aerossois
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
CN1158996C (zh) * 1998-07-24 2004-07-28 杰格研究股份公司 药用气溶胶制剂
CA2338680C (en) * 1998-08-04 2008-10-14 Jago Research Ag Medicinal aerosol formulations
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6926911B1 (en) * 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
AU2000250701B2 (en) * 2000-05-22 2004-07-01 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
AU2001278115A1 (en) * 2000-08-04 2002-02-18 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
WO2002043701A2 (en) * 2000-11-30 2002-06-06 Vectura Limited Method of making particles for use in a pharmaceutical composition
AR036358A1 (es) * 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
ES2745064T3 (es) * 2002-03-01 2020-02-27 Chiesi Farm Spa Formulación superfina de formoterol
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation

Also Published As

Publication number Publication date
HUP0401250A3 (en) 2008-04-28
NZ528640A (en) 2004-06-25
JP4824267B2 (ja) 2011-11-30
DK1372608T3 (da) 2007-12-27
CN100496608C (zh) 2009-06-10
EP1372608B1 (de) 2007-10-10
DE50211045D1 (de) 2007-11-22
SK286394B6 (sk) 2008-09-05
NO20034323L (no) 2003-09-26
AU2002234476B2 (en) 2006-04-27
PT1372608E (pt) 2008-01-04
RU2003131676A (ru) 2005-02-10
AU2002234476C1 (en) 2002-10-15
JP2004525148A (ja) 2004-08-19
SK13342003A3 (sk) 2004-08-03
PL207377B1 (pl) 2010-12-31
NO332848B1 (no) 2013-01-21
CA2442415C (en) 2010-07-20
CZ301676B6 (cs) 2010-05-19
ATE375142T1 (de) 2007-10-15
RU2294737C2 (ru) 2007-03-10
HU229798B1 (en) 2014-07-28
RO121172B1 (ro) 2007-01-30
CA2442415A1 (en) 2002-10-10
ZA200307161B (en) 2005-01-26
CN1499958A (zh) 2004-05-26
WO2002078671A1 (de) 2002-10-10
HUP0401250A2 (hu) 2004-11-29
US20040101483A1 (en) 2004-05-27
NO20034323D0 (no) 2003-09-26
CY1107128T1 (el) 2012-10-24
EP1372608A1 (de) 2004-01-02
CZ20032915A3 (en) 2004-06-16
ES2292713T3 (es) 2008-03-16
HK1064295A1 (en) 2005-01-28

Similar Documents

Publication Publication Date Title
ZA200307161B (en) Medical aerosol formulations
BR0215380A (pt) Pó micronizado farmacêutico ou nutracêutico de liberação imediata e utilização do mesmo
DE60207198D1 (de) Transplantate für die wiederherstellung von osteochondralen schäden
ATE373422T1 (de) Mikroemulsionbildende herbizidkonzentrate, mikroemulsionen und verfahren
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
SG127738A1 (en) Heterocyclic compounds based on n6-substituted adenine, methods of their preparation, their use for preparation of drugs, pharmaceutical preparations containing these compounds
NZ527157A (en) Compositions for delivering bisphosphonates
DK1102579T3 (da) Medicinske aerosolformuleringer
EA200800927A1 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ
WO2007060104A3 (de) Aerosolformulierung für die inhalation enthaltend ein anticholinergikum
DE60105448D1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
MXPA05013637A (es) Inhibidores gsk-3 y usos de los mismos.
WO2007060108A3 (de) Aerosolformulierung für die inhalation enthaltend ein anticholinergikum
IT1320080B1 (it) Composizione per uso farmaceutico o dietetico.
PL1868631T3 (pl) Zastosowanie związków indukujących syntezę białek SIRT przy lub dla otrzymywania kompozycji kosmetycznej lub farmaceutycznej
UY27373A1 (es) Formulaciones de interferón beta-humano
BR0207725A (pt) Promotores do crescimento e/ou da diferenciação de células-tronco hematopoiéticas e/ou progenitores hematopoiéticos
ITMI20022549A1 (it) Composizione quaternaria comprendente come sostanza attiva la propolis.
DE60033416D1 (de) Verwendung von hypoestoxiden als antiparasitäre mittel
BRPI0507144A (pt) formulações em pó
TW200727921A (en) Formulation for prolonged release of active ingredients of medicaments
DE50310932D1 (de) Sporopollenin enthaltende lösliche zusammensetzung und verwendung
WO2004071386A3 (en) Compositions comprising microcapsules containing magnetic nanoparticles and biologically active molecules, their preparation and use
PT1229900E (pt) Formulacoes de farmacos de libertacao prolongada para implantacao
BR0202759A (pt) Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa